AbioCor totally implantable artificial heart. How will it impact hospitals?
Although heart transplantation remains the most effective treatment for severe heart failure, there are far fewer donor hearts available than there are patients who could benefit from them. One approach to addressing this shortfall is the total artificial heart, or TAH. To date, however, no TAH design has been able to achieve one of the ultimate goals of heart replacement: to allow a patient to live a reasonably normal life without being connected to external machinery. A new design, the AbioCor TAH developed by Abiomed Inc., may make this goal achievable. Thanks to a power system that transfers energy through the skin without the aid of wires, the AbioCor--currently undergoing clinical trials in the United States--allows the patient to be completely mobile. The lack of transcutaneous wires also eliminates the primary source of the infections that have plagued TAH patients in the past. Though it is not without drawbacks, the AbioCor could represent a crucial advance in TAH technology. In this Technology Overview, we describe the operation of the AbioCor and discuss its likely impact on hospitals if it is approved for marketing in the United States. We also discuss a related cardiac-support technology: ventricular assist devices (VADs), which may also be used for permanent cardiac support someday.
D016507:Cardiology Service, Hospital / Q000191:economics / Q000639:trends*; D002986:Clinical Trials as Topic; D004867:Equipment Design; D006354:Heart, Artificial / Q000191:economics / Q000592:standards*; D006353:Heart-Assist Devices / Q000191:economics; D017721:Hospital Costs; D006801:Humans; D017060:Patient Satisfaction; D010561:Personnel Staffing and Scheduling; D013673:Technology Assessment, Biomedical; D014481:United States